Safety, feasibility of PrEP for adolescent men who have sex with men

September 5, 2017

Human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) was safe and well-tolerated in a study of adolescent men who have sex with men, although adherence to the daily medication waned and some HIV infections occurred among those with poor adherence, according to an article published by JAMA Pediatrics.

The U.S. Food and Drug Administration approved tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV PrEP in 2012. Since then, clinical trials and demonstration projects have supported the effectiveness of PrEP. But trials did not include adolescents younger than 18 so regulatory agencies were precluded from considering the approval of using TDF/FTC for minors.

Sybil G. Hosek, Ph.D., of the Cook County Health & Hospitals System's Stroger Hospital, Chicago, and coauthors designed Adolescent Medicine Trials Network for HIV/AIDS Interventions113 as an open-label demonstration project and phase 2 safety study for men who have sex with men who are ages 15 to 17 in the United States.

Study participants were recruited from clinics and community partners in six U.S. cities. They had negative HIV test results but were at high risk for and were willing to participate in a behavioral intervention and to accept TDF/FTC as PrEP, which they were provided daily for 48 weeks.

The study enrolled 78 participants with an average age of 16, of whom 29 percent were black, 14 percent were white and 21 percent were white Hispanic.

Over the 48 weeks, 23 sexually transmitted infections were diagnosed in 12 participants and three participants acquired an HIV infection during the study for an HIV seroconversion rate of 6.4 per 100 person-years, according to the results. Among those with seroconversion, tenofovir diphosphate levels were consistent with taking less than an average of two doses per week of the PrEP at the likely time of HIV infection.

Most of the participants had detectable PrEP drug levels throughout the study, with more than 95 percent of participants having detectable levels over the first 12 weeks of treatment with declining levels thereafter, the authors report, noting that challenges to medication adherence among adolescents are commonplace.

Study limitations include its small sample size.

"The waning adherence, especially with quarterly visits, demonstrates that more time, attention and resources may need to be allocated to adolescents who are seeking prevention services," the article concludes.

Explore further: Maraviroc-containing HIV PrEP regimens safe, well tolerated

More information: JAMA Pediatrics (2017). DOI: 10.1001/jamapediatrics.2017.2007

Related Stories

Maraviroc-containing HIV PrEP regimens safe, well tolerated

August 23, 2017
(HealthDay)—Maraviroc (MVC)-containing HIV pre-exposure prophylaxis (PrEP) regimens are well tolerated for preventing HIV infection in uninfected women, according to a study published online Aug. 22 in the Annals of Internal ...

In adolescents, oral Truvada and vaginal ring for HIV prevention are safe, acceptable

July 25, 2017
A monthly vaginal ring and a daily oral tablet, both containing anti-HIV drugs, were safe and acceptable in studies of adolescents, two teams of investigators reported today at the 9th IAS Conference on HIV Science in Paris. ...

Effect of pre-exposure prophylaxis for HIV infection integrated with community health services

November 16, 2015
The rate of acquiring human immunodeficiency virus (HIV) was extremely low despite a high incidence of sexually transmitted infections (STIs) in a study where pre-exposure antiretroviral medication to prevent HIV infection ...

International study finds high levels of adherence to use of rectal microbicide gel

October 20, 2016
Participants enrolled in a rectal microbicide study were just as likely to follow through using an anti-HIV gel with anal sex as they were to using daily oral pre-exposure prophylaxis (PrEP), according to adherence results ...

Patient infected with HIV despite long-term adherence to PrEP

February 2, 2017
(HealthDay)—In a letter to the editor published in the Feb. 2 issue of the New England Journal of Medicine, authors present the case of a Canadian man infected with HIV despite long-term adherence to pre-exposure prophylaxis ...

Maraviroc-containing regimens safe, tolerable when taken for HIV prevention

February 24, 2016
Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk ...

Recommended for you

Asthma drug tied to nightmares, depression

September 20, 2017
(HealthDay)—The asthma medication Singulair (montelukast) appears linked to neuropsychiatric side effects, such as depression, aggression, nightmares and headaches, according to a new review by Dutch researchers.

Parents not confident schools can assist child with chronic disease, mental health

September 18, 2017
If your child had an asthma attack during the school day, would school personnel know how to respond?

Premature infants may get metabolic boost from mom's breast milk

September 14, 2017
The breast milk of mothers with premature babies has different amounts of microRNA than that of mothers with babies born at term, which may help premature babies catch up in growth and development, according to researchers.

Explaining bursts of activity in brains of preterm babies

September 12, 2017
The source of spontaneous, high-amplitude bursts of activity seen in the brains of preterm babies, which are vital for healthy development, has been identified by a team led by researchers at UCL and King's College London.

Why one teenager may need more—or less—sleep than another

August 30, 2017
Sleep problems contribute to a number of mental health issues in adolescents, researchers say. But a lingering question is whether some teens need more—or less—sleep than others to be healthy and at their best.

Study shows probiotics can prevent sepsis in infants

August 17, 2017
A research team at the University of Nebraska Medical Center College of Public Health has determined that a special mixture of good bacteria in the body reduced the incidence of sepsis in infants in India by 40 percent at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.